A PET study examining pharmacokinetics and dopamine transporter occupancy of two long-acting formulations of methylphenidate in adults

International Journal of Molecular Medicine

Volumn 25, Issue 2, 2010, Pages 261-265

  Spencer, Thomas J ^a,b   Bonab, Ali A ^a,b,c   Dougherty, Darin D ^a,b   Martin, Jessica ^a   McDonnell, Tara ^a   Fischman, Alan J ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

Attention deficit hyperactivity disorder; Binding potential; Controlled release; Dopamine transporter; Methylphenidate; Positron emission tomography

Indexed keywords

DOPAMINE TRANSPORTER; LONG ACTING DRUG; METHYLPHENIDATE;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED RELEASE FORMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGING; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CHI-SQUARE DISTRIBUTION; DELAYED-ACTION PREPARATIONS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; HUMANS; METHYLPHENIDATE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; YOUNG ADULT;

EID: 73649105495     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000339     Document Type: Article

References (13)

1. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 56: 1073-1086, 1999.
2. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R and Pappas N: Dopamine transporter occupancies in the human brain induced by theraputic doses of oral methylphenidate. Am J Psychiatry 155: 1325-1331, 1988.
3. 127I]Altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse 39: 332-342, 2001.
4. Fischman AJ, Bonab AA, Babich JW, Alpert NM, Rauch SL, Elmaleh DR, Shoup TM, Williams SA and Rubin RH: Positron emission tomographic analysis of central 5-hydroxytryptamine-2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J Pharmacol Exp Ther 279: 939-947, 1996.
5. Fischman AJ, Alpert NM and Rubin RH: Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action. Clin Pharmacokinet 41: 581-602, 2002.
6. Fischman AJ, Alpert NM, Babich JW and Rubin RH: The role of positron emission tomography in pharmacokinetic analysis. Drug Metab Rev 29: 923-956, 1997.
7. Salazar DE and Fischman AJ: Central nervous system pharmacokinetics of psychiatric drugs. J Clin Pharmacol (Suppl): S10-S12, 1999.
8. Christian BT, Livni E, Babich JW, Alpert NM, Dischino DD, Ruediger E, Salazar DE, Ford NF and Fischman AJ: Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography. J Pharmacol Exp Ther 279: 325-331,1996.
9. Spencer TJ, Biederman J, Ciccone PE, Madras BK, Dougherty DD, Bonab AA, Livni E, Parasrampuria DA and Fischman AJ: PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 163: 387-395, 2006.
10. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, Lindemulder E and Wigal S: Development of a new once-a-day formulation of methylphenidate for the treatment of ADHD: Proof of concept and proof of product studies. Arch Gen Psychiatry 60: 204-211, 2003.
11. Gonzalez MA, Pentikis HS and Andrl N: Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 40: 175-184, 2002.
12. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ and Hatch SJ: A comparison of once-daily extended-release methylphenidate formulations in children with ADHD in the laboratory school (The Comacs study). Pediatrics 113: E206-E216, 2004.
13. Lammers CH, D'Souza U, Qin ZH, Lee SH, Yajima S and Mouradian MM: Regulation of striatal dopamine receptors by estrogen. Synapse 34: 222-227, 1999.